Skip to content

Application of Liposomal Bupivacaine in Posterior Subcostal Quadratus Lumborum Block for Postoperative Analgesia Following Gynecological Single-Incision Laparoscopic Surgery

Application of Liposomal Bupivacaine in Posterior Subcostal Quadratus Lumborum Block for Postoperative Analgesia Following Gynecological Single-Incision Laparoscopic Surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104156
Enrollment
Unknown
Registered
2025-06-12
Start date
2025-06-12
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative analgesia after gynecological single-port surgery

Interventions

LB:Under ultrasound guidance, bilateral QLB was performed at the subcostal region through the posterior approach. 30 ml of 0.44% bupivacaine liposome was injected on each side.
NC:Under ultrasound guidance, bilateral QLB was performed at the subcostal region through the posterior approach. 30 ml of normal saline was injected into each side.

Sponsors

The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: a. Age 18-65 years old, ASA classification I-II level b. Planned for elective gynecological single-port laparoscopic surgery (such as ovarian cystectomy, total hysterectomy, bilateral adnexectomy, etc.) c. Voluntarily sign the informed consent form

Exclusion criteria

Exclusion criteria: Exclusion criteria: a. History of local anesthetic allergy or opioid dependence; b. Coagulation dysfunction (INR > 1.4, PLT 3 months; d. Severe heart or lung diseases or liver and kidney dysfunction; e. Long-term use of opioids or glucocorticoids (> 3 months, prednisone = 5mg/d equivalent dose); f. Presence of cognitive impairment preventing the operation of PCIA equipment; g. Pregnant or lactating women; h. Surgery duration > 180 minutes.

Design outcomes

Primary

MeasureTime frame
Total consumption of oxycodone (mg) 72 hours after surgery;Number of PCIA compressions and the time of the first compression (in postoperative hours);

Secondary

MeasureTime frame
The area under the curve of the resting/moving NRS score within 72 hours after the operation;The intraoperative dosage of remifentanil/sufentanil and the dosage of oxycodone in the recovery room (in µg/kg/h);The change gradient of the QoR-15 score at 24/48/72 hours;Dynamic changes in serum IL-6/TNF-a levels;First defecation/elimination time (hours);Abdominal distension score (0 - 10 points);

Countries

China

Contacts

Public ContactMa Rong

The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial Hospital

kongqiuyue@njmu.edu.cn+86 138 5156 1882

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026